Figure 1.

Schematic illustration of the overall study design. The differences of TCR repertoire between AML patients and healthy donors were compared on BM and PB samples by evaluating several indicators, e.g., the CDR3β diversity, V-J usage, clonal expansion and sequence overlap. CD8⁺ T cells in BM and PB from AML patients and healthy donors were phenotypically analyzed based on the coordinated expression of CD45RA and CCR7. The dynamics of TCR repertoire, phenotypic composition, expression levels of co-inhibitory receptors including PD-1, TIM3, TIGIT, and TCR repertoire distribution in PD-1^-/PD-1⁺ T cells were assessed in BM CD8⁺ T cells from AML patients before and after chemotherapy.